CG0070: A Genetically Modified Immunotherapy for Non-Muscle Invasive Bladder Cancer


The first patient in CG Oncology's phase 2 study of CG0070 was dosed in December 2020.

"With the bladder indication, we're essentially giving the virus locally through the catheter into the bladder. It's a really safe procedure. We don't have or expect any systemic toxicities of the over-100 patients so far in over 800 installations.”

CG Oncology is focused on developing immunotherapies for the treatment of bladder cancer, with their lead program, CG0070, a prime contender. The oncolytic immunotherapy uses a genetically modified oncolytic adenovirus delivered through a catheter to target and destroy bladder tumor cells through their defective retinoblastoma pathway.

The first patient was dosed in the phase 2 CORE-001 trial (NCT04387461) of CG0070 in combination with pembrolizumab (Keytruda; Merck) for non-muscle-invasive bladder cancer unresponsive to bacillus calmette-guerin in December 2020. The trial aims to evaluate the safety and efficacy of CG0070 plus Keytruda in up to 35 patients.

GeneTherapyLive spoke with Arthur Kuan, chief executive officer, CG Oncology, to learn more about the company’s background and development of CG0070. He discussed some data investigators have collected so far in the phase 2 trial. 

CG Oncology announces first patient dosed in phase 2 clinical trial of CG0070, an oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab) for non-muscle-invasive bladder cancer unresponsive to bacillus calmette-guerrin. News release. CG Oncology. December 9, 2020. Accessed July 29, 2021.
Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
© 2024 MJH Life Sciences

All rights reserved.